What is the recommended evaluation and management for a patient with non‑alcoholic fatty liver disease (NAFLD) and non‑alcoholic steatohepatitis (NASH)?

Management of NAFLD and NASH

Initial Risk Stratification

All patients with suspected NAFLD require non-invasive fibrosis assessment using FIB-4 score or NAFLD Fibrosis Score to stratify risk, followed by transient elastography for intermediate-risk patients. 1, 2

• Perform baseline laboratory evaluation including CBC, comprehensive metabolic panel (AST, ALT, bilirubin, alkaline phosphatase), INR, fasting glucose or HbA1c, and lipid profile. 3
• Obtain abdominal ultrasound to document hepatic steatosis. 3
• Exclude competing etiologies: hepatitis B and C serologies, autoantibodies (ANA, anti-smooth muscle, antimitochondrial), serum ferritin, and α-1 antitrypsin levels. 3
• Verify alcohol consumption is <14 drinks per week for women and <21 drinks per week for men. 3
• Discontinue hepatotoxic medications: corticosteroids, amiodarone, methotrexate, tamoxifen, estrogens, tetracyclines, and valproic acid. 2, 4

Reserve liver biopsy for patients with diabetes or metabolic syndrome, those with FIB-4 >2.67 or liver stiffness >12 kPa, or when clinical signs suggest cirrhosis (thrombocytopenia, AST > ALT, hypoalbuminemia). 1, 3

---

Lifestyle Modification: First-Line Therapy for All Patients

Target 7–10% total body weight loss through combined dietary modification and structured exercise; this is the only proven treatment for simple steatosis and remains foundational even when pharmacotherapy is added for advanced disease. 1, 2

Weight Loss Targets and Expected Outcomes

• 5–7% weight loss: Reduces hepatic steatosis and inflammation in approximately 65% of patients. 2
• ≥7% weight loss: Achieves NASH resolution in 64% of patients. 2
• ≥10% weight loss: Results in fibrosis regression in 45% and stabilization in the remaining 55%. 2, 4

Weight loss must be gradual (≤1 kg per week); rapid weight loss exceeding this rate can precipitate acute hepatic decompensation or worsen portal inflammation and fibrosis. 2, 4

Dietary Prescription

Adopt a Mediterranean diet pattern as the primary dietary approach—this reduces liver fat even without weight loss. 2, 3

• Emphasize vegetables, fruits, whole grains, legumes, nuts, fish, and olive oil; limit red and processed meats. 2, 5
• Create a daily caloric deficit of 500–1000 kcal (targeting 1200–1500 kcal/day for women, 1500–1800 kcal/day for men). 2, 4
• Completely eliminate fructose-containing beverages and sugar-sweetened drinks. 2
• Replace saturated fats with polyunsaturated (especially omega-3) and monounsaturated fats. 2

Exercise Prescription

Prescribe 150–300 minutes per week of moderate-intensity aerobic exercise OR 75–150 minutes per week of vigorous-intensity exercise. 1, 2

• Vigorous-intensity aerobic activity (≥6 METs) is required to achieve fibrosis improvement; moderate-intensity exercise alone does not improve NASH severity or fibrosis. 2
• Include resistance training twice weekly to augment metabolic benefits. 2, 4
• Physical activity reduces hepatic steatosis even without significant weight loss. 1

---

Pharmacotherapy: Reserved for Biopsy-Proven NASH with Significant Fibrosis (≥F2)

No pharmacologic therapy should be prescribed for simple steatosis or mild NAFLD without biopsy-proven NASH and significant fibrosis. 2

For Patients WITH Type 2 Diabetes and Biopsy-Proven NASH

GLP-1 receptor agonists (liraglutide, semaglutide) are first-line pharmacotherapy, achieving NASH resolution in 39–59% versus 9–17% with placebo while also promoting weight loss and cardiovascular risk reduction. 1, 2, 4

• Pioglitazone 30 mg daily is an alternative option that improves all histologic features except fibrosis and achieves higher NASH resolution rates than placebo. 1, 2, 4

For Non-Diabetic Patients with Biopsy-Proven NASH (No Cirrhosis)

Vitamin E 800 IU daily is the most established therapy, improving steatohepatitis and liver histology through antioxidant properties. 1, 2, 4

• Do not use vitamin E in diabetic patients or those with cirrhosis due to mixed or lacking evidence. 4

Agents NOT Recommended for NAFLD Treatment

Metformin should not be used as specific NAFLD treatment—it has minimal impact on liver fat and lacks robust histologic benefit. 2

• Metformin may be continued solely for diabetes management when renal function permits. 2

---

Management of Metabolic Comorbidities

Aggressively treat all components of metabolic syndrome—cardiovascular disease, not liver disease, is the primary cause of mortality in NAFLD patients without cirrhosis. 1, 2

Dyslipidemia

Statins are safe in NAFLD and should be used to treat dyslipidemia despite liver disease—they reduce hepatocellular carcinoma risk by 37% and hepatic decompensation by 46%. 2, 4

• Statins provide beneficial pleiotropic properties beyond lipid lowering and are recommended even in patients with compensated cirrhosis. 4

Diabetes Management

Prioritize GLP-1 receptor agonists or SGLT-2 inhibitors in patients with type 2 diabetes and NAFLD, following American Diabetes Association guidelines. 1

• Optimize glycemic control to reduce risk of hepatocellular carcinoma and liver-related complications. 2

Hypertension

• Treat hypertension according to standard guidelines. 2, 3

Screening

• Perform annual screening for type 2 diabetes, hypertension, and dyslipidemia in all NAFLD patients. 2

---

Alcohol Consumption Guidance

In pre-cirrhotic NAFLD, limit alcohol to ≤1 drink per day for women and ≤2 drinks per day for men. 2

In NASH-related cirrhosis, total abstinence is mandatory to reduce hepatocellular carcinoma risk. 2

---

Bariatric Surgery

Consider bariatric surgery for patients with BMI ≥35 kg/m² who have failed lifestyle interventions—approximately 85% achieve histologic NASH resolution at one year post-procedure. 2, 4

• Effectiveness and safety have not been established in patients with cirrhosis or very high BMI with advanced fibrosis. 1, 2
• Bariatric surgery should be performed by well-established programs. 1, 4

---

Monitoring Strategy

For Patients WITHOUT Cirrhosis

• Monitor liver enzymes (ALT, AST) periodically. 1
• Reassess fibrosis using non-invasive tests (FIB-4, NAFLD Fibrosis Score, or transient elastography) every 1–3 years to track disease progression or treatment response. 3, 4

For Patients WITH Cirrhosis or Advanced Fibrosis (≥F3)

These patients require multidisciplinary management coordinated by a hepatologist. 1

• Abdominal ultrasound every 6 months for hepatocellular carcinoma surveillance. 1, 2, 4
• Esophagogastroduodenoscopy (EGD) for variceal screening. 1, 2, 4
• Transplant referral when appropriate. 1, 2

---

Critical Pitfalls to Avoid

• Do not prescribe pharmacotherapy for simple steatosis or mild NAFLD without biopsy-proven NASH and significant fibrosis. 2
• Do not pursue rapid weight loss exceeding 1 kg per week—this can worsen liver disease or precipitate acute hepatic failure. 2
• Do not use metformin as specific NAFLD treatment—it lacks hepatic efficacy. 2
• Do not withhold statins in NAFLD patients with dyslipidemia—they are safe and hepatoprotective. 2, 4
• Do not perform routine screening of asymptomatic individuals—systematic primary-care screening is not currently recommended. 3